Answers are grounded in this paper and cite their sources.
Systematic review finds therapeutic potential of neostigmine and pyridostigmine in pediatric CIPO, indicating need for more clinical trials.
Pyridostigmine and neostigmine may represent therapeutic options for pediatric CIPO, with neostigmine appearing particularly effective in acute settings and pyridostigmine more suited to chronic management. Although current evidence supports both safety and potential efficacy, robust clinical trials are essential before these agents can be integrated into standard care protocols.
No takes yet. Share an insight, caveat, or question.
Cocchi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: